NEOS Investment Management LLC Acquires 5,736 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

NEOS Investment Management LLC increased its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 43.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,040 shares of the biotechnology company’s stock after buying an additional 5,736 shares during the period. NEOS Investment Management LLC’s holdings in Ascendis Pharma A/S were worth $2,621,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB bought a new position in shares of Ascendis Pharma A/S in the third quarter worth about $30,000. Jones Financial Companies Lllp increased its holdings in shares of Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 197 shares in the last quarter. Blue Trust Inc. raised its position in Ascendis Pharma A/S by 415.2% in the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 328 shares during the last quarter. Groupama Asset Managment acquired a new position in Ascendis Pharma A/S during the 3rd quarter worth $60,000. Finally, GAMMA Investing LLC boosted its position in Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 214 shares during the last quarter.

Ascendis Pharma A/S Trading Down 2.1 %

ASND stock opened at $154.68 on Friday. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $169.37. The business’s 50-day moving average price is $144.16 and its two-hundred day moving average price is $137.01. The firm has a market cap of $9.39 billion, a PE ratio of -21.79 and a beta of 0.62.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.64. On average, analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on ASND. UBS Group initiated coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a “buy” rating and a $196.00 price target on the stock. JPMorgan Chase & Co. upped their target price on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, March 18th. The Goldman Sachs Group lifted their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Morgan Stanley set a $180.00 price objective on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. Finally, Evercore ISI lifted their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday, February 18th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $204.64.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.